Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.65 USD | +2.52% | 0.00% | -56.18% |
Jun. 04 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
1st Jan change | Capi. | |
---|---|---|
-56.18% | 1.79B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.42% | 22.78B | |
-10.46% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024